CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 50 target
Drug / intervention
Sulfasalazinedrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Histologically confirmed stage IV metastatic colorectal cancer
  • ✓Age 18-65 years
  • ✓Women of childbearing age on acceptable contraception
  • ✓No myelosuppression
Key exclusion· 8
  • ✕Pregnant or lactating women
  • ✕Concurrent active cancer from non-colorectal primary
  • ✕Known allergy to sulfasalazine or metabolites
  • ✕Nephrolithiasis, severe vomiting, or severe diarrhea

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06134388
NCT06134388Phase 3RecruitingUpdate OverdueUpdated 31mo ago · Completion was 10mo ago
Enrollment Stalled
Update Overdue
CompareCT.gov

Clinical Study Evaluating the Efficacy and Safety of Sulfasalazine in Patients With Metastatic Colorectal Cancer

Tanta University·interventional·Posted Nov 18, 2023·Updated Nov 18, 2023

In Brief

A Phase 3 clinical trial evaluating Sulfasalazine for Metastatic Colorectal Cancer. Currently recruiting, targeting 50 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesEgypt
Collaborators--

Timeline

Phase 3Recruiting
202420252026
First PostedNov 18, 2023
Enrollment StartSep 1, 2023
Primary CompletionSep 1, 2025
Study CompletionSep 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 2.6 years ago

Interventions

Sulfasalazinedrug

Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.